KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.

KRAS/TP53 co-mutation predicts ICI benefit in univariate and multivariate survival analyses and is associated with unique molecular tumour features. Mutation testing of the two genes can be easily implemented using small NGS panels.